SCHEMBL8300245

SCHEMBL8300245

Cc1ccccc1-c1ccc(C[C@H](NC(=O)OC(C)(C)C)C(=O)O)cc1C

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.59
PTPN1 P18031 3/20 0.54
PPARA Q07869 6/20 0.52
PPARG P37231 5/20 0.52
CTSS P25774 6/20 0.52
CTSK P43235 5/20 0.52
CTSB P07858 4/20 0.52
ITGB3 P05106 2/20 0.51
ITGA2B P08514 2/20 0.51
PPARD Q03181 2/20 0.50
CTSL P07711 1/20 0.50
ITGB1 P05556 1/20 0.48
ITGAV P06756 1/20 0.48
ITGB5 P18084 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8300269 0.90 KLK5 (0.54) ACEPTPN1PPARAPPARGCTSS
SCHEMBL13227703 0.87 PTPN1 (0.63) ACEPTPN1PPARAPPARGCTSS
SCHEMBL10099987 0.86 ACE (0.60) ACEPTPN1PPARAPPARGCTSS
SCHEMBL17933020 0.86 ACE (0.60) ACEPTPN1PPARAPPARGCTSS
SCHEMBL15565481 0.83 ACE (0.58) ACEPTPN1PPARAPPARGCTSS
SCHEMBL13286814 0.83 ACE (0.58) ACEPTPN1PPARAPPARGCTSS
SCHEMBL6157428 0.83 ACE (0.51) ACEPTPN1PPARAPPARGCTSS
SCHEMBL18553988 0.82 ACE (0.57) ACEPTPN1PPARAPPARGCTSS
SCHEMBL8657006 0.82 ACE (0.60) ACEPTPN1PPARAPPARGCTSS
SCHEMBL11032508 0.82 ACE (0.60) ACEPTPN1PPARAPPARGCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210552-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2010-08-19 US disclosed
US-20100210552-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2010-08-19 US disclosed
US-20070287670-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-12-13 US disclosed
US-7238670-B2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
WO-2004094461-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed
WO-2003033671-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287670-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS GLP1R, IAPP, GIPR ACE 1664/4885PTPN1 1186/4885PPARA 720/4885
US-20100210552-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS GLP1R, IAPP, GIPR ACE 1664/4885PTPN1 1186/4885PPARA 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.